Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8418613 | Journal of Immunological Methods | 2012 | 13 Pages |
Abstract
This is the first report of the development and characterization of a panel of fully human antibodies against EPO suitable as reference reagents. The characteristics of antibodies within the panel were selected based on the prevalence of non-neutralizing IgG and IgM antibodies in non-PRCA patients and neutralizing IgG antibodies, including IgG1 and IgG4, in antibody-mediated PRCA subjects. The reference panel includes antibodies of high- and low-affinity with binding specificity to neutralizing and non-neutralizing erythropoietin epitopes. The subclass of human antibodies in this reference panel includes an IgG1, IgG2, and IgG4, as well as an IgM isotype. This antibody panel could help select appropriate immunogenicity assays, guide validation, and monitor assay performance. Further, this human anti-ESA antibody panel may help set the limits of each assay platform in terms of the full repertoire of the anti-ESA antibodies, and may facilitate standardization of ESA immunogenicity reporting across assay platforms.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Daniel T. Mytych, Troy E. Barger, Chadwick King, Stephanie Grauer, Raj Haldankar, Eric Hsu, Michelle Min Wu, Mukta Shiwalkar, Sergio Sanchez, Andrew Kuck, Francesca Civoli, Jilin Sun, Steven J. Swanson,